SL Science licensor files FDA drug master file for GDT exosomes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
August 27, 2026 8:00 AM EDTTAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (SL Science or the Company) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, today highlighted the filing of a new Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). The DMF, filed under number 044612, covers exosomes derived from Gamma Delta T (GDT) cells. It was filed by JY BioMed Co., Ltd. (JY BioMed), the intellectual property holder of the GDT platform and SL Sciences licensor.
This filing marks a significant milestone, as it... More
